Oramed Pharmaceuticals (NASDAQ: ORMP) engages in the technology of oral delivery solutions for drugs currently delivered via injection. Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. The company is focused on revolutionizing the treatment of diabetes through its proprietary flagship product, ORMD-0801, an orally ingestible insulin capsule. Oramed has completed multiple phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. Oramed is also developing ORMD-0901, an oral GLP-1 analog capsule. For more information, visit the company’s website at www.oramed.com.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com